Seeking Alpha

Seeking Alpha Portfolio App for iPad

8,634 people get TEVA articles and Market Currents by email alert.

Get email alerts on TEVA »

TEVA

Teva Pharmaceutical Industries Limited

6/19/2013, 5:47 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 17, 2:37 PM The Supreme Court's ruling regarding challenges to generic drug deals "is a significant victory for American consumers, American taxpayers, and free markets," the FTC says, noting that the ruling against "pay-for-delay agreements" makes it clear that these deals are subject to antitrust scrutiny. As MarketWatch notes however, stocks have pretty much shrugged it off with Actavis (ACT -1%) and AbbVie (ABBV -0.8%) down a bit, Teva (TEVA +0.3%) acting like nothing happened, and Impax (IPXL -0.7%) down only fractionally. Comment! [Healthcare]
Monday, June 17, 10:44 AM In an effort to expand its pipeline of repiratory products, Teva Pharmaceutical (TEVA +0.4%) acquires MicroDose Therapeutx, a privately-held pharmaceutical and drug delivery company. Under the terms of the deal, TEVA will pay $40M up front, with additional payments of up to $125M for milestones and tiered royalty payments for the commercialization of MDT-637 and an earlier stage Asthma/COPD medicine. 1 Comment [Healthcare, M&A, Global & FX]
Wednesday, June 12, 9:33 AM More on Protonix settlement: Teva (TEVA -0.9%) expects to incur a charge of $930M in Q2, adding to a $670M provision that the company took in its 2012 earnings. Teva may have up to $560M of net insurance coverage in connection with the settlement. Comment! [Healthcare]
Wednesday, June 12, 8:39 AM More on Protonix settlement: Teva (TEVA -1.3%) will pay $1.6B of the $2.15B, half in 2013 and the rest by October 2014, while Sun will pay its $550M share this year. The settlement follows a legal battle of almost 10 years in which a jury found that Teva and Sun violated the patent by launching generic versions of Protonix prior to the expiry of its patent in 2011. The deal also comes after the start of a trial to determine damages. Pfizer (PFE) +0.8%. (PR) 4 Comments [Healthcare, Top Stories]
Wednesday, June 12, 8:22 AM Teva's (TEVA -1.8%) and Active Biotech's (ATVBF.PK) oral laquinimod drug improved renal function in patients with active lupus nephritis in Phase IIa trials. Lupus is a chronic and often disabling autoimmune disease that can lead to kidney failure. Teva and Active Biotech believe the data provide the rationale for further studies of laquinimod. (PR) 1 Comment [Healthcare]
Wednesday, June 12, 7:56 AM Pfizer (PFE) and Takeda (TKPHF.PK) obtain a $2.15B settlement from Teva (TEVA) and India's Sun for breaching a patent of Pfizer's and Nycomed's (now part of Takeda) blockbuster acid reflux medicine Protonix. Pfizer will receive 64% of the money and Takeda the rest. (PR) Comment! [Breaking News, Healthcare, Top Stories]
Tuesday, June 11, 8:24 AM The Justice Department will end restrictions on the one-pill version of morning-after emergency contraception. Until recently, only women aged at least 17 could buy the pill without a prescription. The decision comes after an appeals court said last week that an older two-pill version should be available over the counter on an unlimited basis. Companies affected include Teva (TEVA), Perrigo (PRGO) and Actavis (ACT). (previous) 1 Comment [Healthcare]
Thursday, June 6, 9:06 AM A federal appeals court has ordered the FDA to make an older version of the morning after contraceptive, which comprises two pills, available to women, irrespective of age. However, the one-pill version will still be subject to age limits. The FDA had challenged an order to eliminate age and other restrictions on who may buy morning-after, or "Plan B" pills. The appeals court will hear the overall case - on access to contraceptives - on an expedited basis. Companies affected include Teva (TEVA), Perrigo (PRGO) and Actavis (ACT). Comment! [Healthcare]
Monday, June 3, 8:31 AM The EU's Committee for Medicinal Products for Human Use recommends approving Teva's (TEVA +0.2%) Lonquex drug for the treatment of neutropenia, which is a side-effect of chemotherapy that reduces the level of a patient's white bloods cells and exposes him/her to serious bacterial infections. Teva expects a decision from the EU within the next few months. Comment! [Healthcare]
Thursday, May 30, 9:54 AM Teva (TEVA -0.1%) will pay 336M shekels ($91M) in taxes under an amendment to Israel's Law for the Encouragement of Capital Investments and could pay a further amount by November. The law allows a company to use tax-exempt profits earned before the end of 2011 to distribute dividends as long it pays certain reduced taxes. 1 Comment [Healthcare, Dividends]
Thursday, May 30, 9:45 AM The FDA will review Teva's (TEVA -0.4%) application for its Copaxone 40 mg Multiple Sclerosis drug, which would be given three times a week rather than every day, as is the case with the lower-strength 20 mg form of the treatment. (PR) Comment! [Healthcare]
Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
Wednesday, May 8, 9:00 AM Alexza Pharmaceuticals (ALXA) announces an exclusive U.S. license deal for Adasuve with Teva Pharmaceutical (TEVA). Nice deal for Alexza - it will receive an upfront payment of $40M with eligibility for another $195M based on milestones. Conference call to discuss is about to begin. Shares remains halted. (PR) Comment! [Healthcare, Breaking News]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Friday, May 3, 5:43 PM An FDA panel has voted 17-1 that Amgen's (AMGN) blood-boosting drugs would benefit radiation survivors in the event of a nuclear attack. The drugs, known as Leukocyte growth factor drugs, are normally given to cancer patients to combat the effects of chemotherapy. The panel observed monkeys exposed to radiation, and those given AMGN's Neupogen showed a greater likelihood of survival, and the FDA says it's likely to provide the same benefit to people as well. Comment! [Healthcare]
Thursday, May 2, 7:03 AM Teva Pharma (TEVA): Q1 EPS of $1.12 beats by $0.01. Revenue of $4.9B beats by $0.05B. (PR) Comment! [Earnings, Breaking News, Healthcare]

1
2
3
4
5
6
...
15
Next Page